185 related articles for article (PubMed ID: 23722308)
1. Immunocryosurgery for non-superficial basal cell carcinoma: a pro-spective, open-label phase III study for tumours ≤ 2 cm in diameter.
Gaitanis G; Bassukas ID
Acta Derm Venereol; 2014 Jan; 94(1):38-44. PubMed ID: 23722308
[TBL] [Abstract][Full Text] [Related]
2. Cryosurgery during Imiquimod (Immunocryosurgery) for Periocular Basal Cell Carcinomas: An Efficacious Minimally Invasive Treatment Alternative.
Gaitanis G; Kalogeropoulos CD; Bassukas ID
Dermatology; 2016; 232(1):17-21. PubMed ID: 26583773
[TBL] [Abstract][Full Text] [Related]
3. Immunocryosurgery for basal cell carcinoma: results of a pilot, prospective, open-label study of cryosurgery during continued imiquimod application.
Gaitanis G; Nomikos K; Vava E; Alexopoulos EC; Bassukas ID
J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1427-31. PubMed ID: 19555364
[TBL] [Abstract][Full Text] [Related]
4. Immunocryosurgery for non-superficial basal cell carcinomas ≤ 20 mm in maximal diameter: Five-year follow-up.
Gaitanis G; Bassukas ID
J Geriatr Oncol; 2019 May; 10(3):475-478. PubMed ID: 30219274
[TBL] [Abstract][Full Text] [Related]
5. Office-based treatment of basal cell carcinoma with immunocryosurgery: feasibility and efficacy.
Nakuçi M; Bassukas ID
Acta Dermatovenerol Alp Pannonica Adriat; 2013; 22(2):35-8. PubMed ID: 23836356
[TBL] [Abstract][Full Text] [Related]
6. Cryosurgery is more effective in the treatment of primary, non-superficial basal cell carcinomas when applied during and not prior to a five week imiquimod course: a randomized, prospective, open-label study.
Gaitanis G; Alexopoulos EC; Bassukas ID
Eur J Dermatol; 2011; 21(6):952-8. PubMed ID: 21926038
[TBL] [Abstract][Full Text] [Related]
7. Large facial basal cell carcinoma treated with multimodal combination therapy.
Rubenzik MK; Schwartz LR; Humphreys TR
Cutis; 2011 Oct; 88(4):182-4. PubMed ID: 22106726
[TBL] [Abstract][Full Text] [Related]
8. Alterations in the inflammatory cells infiltrating basal cell carcinomas during immunocryosurgery.
Nomikos K; Lampri E; Spyridonos P; Bassukas ID
Arch Dermatol Res; 2019 Aug; 311(6):499-504. PubMed ID: 31115658
[TBL] [Abstract][Full Text] [Related]
9. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
Vidal D; Matías-Guiu X; Alomar A
Clin Exp Dermatol; 2004 Sep; 29(5):518-25. PubMed ID: 15347339
[TBL] [Abstract][Full Text] [Related]
10. Imiquimod can be combined with cryosurgery (immunocryosurgery) for locally advanced periocular basal cell carcinomas.
Gaitanis G; Kalogeropoulos C; Bassukas ID
Br J Ophthalmol; 2011 Jun; 95(6):890-2. PubMed ID: 21378006
[No Abstract] [Full Text] [Related]
11. Immunocryosurgery for patients with therapeutically challenging basal cell carcinomas: report of two representative cases.
Gaitanis G; Nomikos K; Vlachos C; Bassukas ID
J Dermatolog Treat; 2012 Feb; 23(1):70-1. PubMed ID: 20964570
[No Abstract] [Full Text] [Related]
12. Treatment of nodular basal cell carcinoma with cryotherapy and reduced protocol of imiquimod.
Moutran R; Maatouk I; Stephan F; Tomb R
Cutis; 2012 Nov; 90(5):256-7. PubMed ID: 23270198
[TBL] [Abstract][Full Text] [Related]
13. The Feasibility of Immunocryosurgery in the Treatment of Non-Superficial, Facial Basal Cell Carcinoma That Relapsed after Standard Surgical Excision: An Experience Report from Two Centers.
Gaitanis G; Zampeta A; Tsintzou P; Fillis G; Seretis K; Feldmeyer L; Bassukas I
Curr Oncol; 2022 Nov; 29(11):8475-8482. PubMed ID: 36354728
[TBL] [Abstract][Full Text] [Related]
14. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial.
Peris K; Campione E; Micantonio T; Marulli GC; Fargnoli MC; Chimenti S
Dermatol Surg; 2005 Mar; 31(3):318-23. PubMed ID: 15841634
[TBL] [Abstract][Full Text] [Related]
15. A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma.
Tillman DK; Carroll MT
J Drugs Dermatol; 2008 Jan; 7(1 Suppl 1):s7-14. PubMed ID: 18277457
[TBL] [Abstract][Full Text] [Related]
16. Intralesional bevacizumab as in-add adjuvant to immunocryosurgery for locally advanced basal cell carcinoma.
Gaitanis G; Bassukas I
J Eur Acad Dermatol Venereol; 2014 Aug; 28(8):1117-21. PubMed ID: 25243268
[TBL] [Abstract][Full Text] [Related]
17. Immunocryosurgery - an effective combinational modality for Bowen's disease.
Gaitanis G; Bassukas ID
Dermatol Ther; 2016 Sep; 29(5):334-337. PubMed ID: 27272913
[TBL] [Abstract][Full Text] [Related]
18. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up.
Schiessl C; Wolber C; Tauber M; Offner F; Strohal R
J Drugs Dermatol; 2007 May; 6(5):507-13. PubMed ID: 17679185
[TBL] [Abstract][Full Text] [Related]
19. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks.
Quirk C; Gebauer K; Owens M; Stampone P
Australas J Dermatol; 2006 Nov; 47(4):258-65. PubMed ID: 17034468
[TBL] [Abstract][Full Text] [Related]
20. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion.
Sterry W; Ruzicka T; Herrera E; Takwale A; Bichel J; Andres K; Ding L; Thissen MR
Br J Dermatol; 2002 Dec; 147(6):1227-36. PubMed ID: 12452875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
